Original language | English (US) |
---|---|
Pages (from-to) | 1822-1826 |
Number of pages | 5 |
Journal | Blood |
Volume | 140 |
Issue number | 16 |
DOIs | |
State | Published - Oct 20 2022 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Blood, Vol. 140, No. 16, 20.10.2022, p. 1822-1826.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma
AU - Soumerai, Jacob D.
AU - Rosenthal, Allison
AU - Harkins, Shannon
AU - Duffy, Jessica
AU - Mecca, Carmen
AU - Wang, Yingbing
AU - Grewal, Ravinder K.
AU - El-Jawahri, Areej R.
AU - Liu, Huiyun
AU - Menard, Cedric
AU - Dogan, Ahmet
AU - Yang, Lei
AU - Rimsza, Lisa M.
AU - Bantilan, Kurt
AU - Martin, Haley
AU - Lei, Matthew
AU - Mohr, Sydney
AU - Kurilovich, Anna
AU - Kudryashova, Olga
AU - Postovalova, Ekaterina
AU - Nardi, Valentina
AU - Abramson, Jeremy S.
AU - Chiarle, Roberto
AU - Zelenetz, Andrew D.
AU - Louissaint, Abner
N1 - Funding Information: Conflict-of-interest disclosure: J.D.S. reports consulting fees from Abbvie, AstraZeneca, Beigene, Biogen, Bristol Myers Squibb, Roche, TG Therapeutics, and Verastem, and research funding from Adaptive Biotechnologies, Beigene, BostonGene, Genentech/Roche, GlaxoSmithKline, MEI, Moderna, and TG Therapeutics. A.D. reports consulting fees from Physician's Education Resource, Seattle Genetics, Takeda, EUSA Pharma, and Abbvie, and research funding from Roche and Takeda. M.L. reports consulting fees for AbbVie, AstraZeneca, Epizyme, Fresenius Kabi, and Intervention Insights. V.N. reports consulting fees from Lilly. J.S.A. reports consulting fees from Abbvie, Bayer, Celgene, Gilead, Juno Therapeutics, Kite Pharma, Genentech, Amgen, Novartis, Karyopharm, Verastem, Janssen, Merck, and Seattle Genetics. A.D.Z. reports consulting fees from Adaptive Biotechnologies, Abbvie, Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Celgene, Genentech/Roche, Gilead, MEI Pharma, MorphoSys, NCCN, Novartis, and Verastem, data safety monitoring committee membership for BMS, Celgene, and Juno, data safety monitoring committee membership chair for Beigene, and research funding from MEI Pharma, Gilead, Beigene, and Roche. A.K., O.K., and E.P. report employment at BostonGene. The remaining authors declare no competing financial interests.The authors thank the patients and their families. This work was made possible through the MGH Lymphoma Translational Research and Biobanking Collaborative supported by the Scott Nathan and Laura DeBonis Fund for Clinical Research (J.S.A.), and further supported by philanthropic funding from an anonymous donor (A.L.), the Jonathan Kraft Translational Research Award (J.D.S. and A.L.), and the National Institutes of Health National Cancer Institute (5R01CA196703) (R.C.). Contribution: J.D.S. and A.L. had full access to the data and were responsible for data collection, data analysis, and data interpretation, wrote the first draft of the manuscript, and were responsible for manuscript submission; A.R. A.D.Z. Y.W. R.K.G. A.R.E.-J. S.H. J.D. C. Mecca, A.D. H.L. C. Menard, L.Y. L.R. K.B. H.M. M.L. S.M. A.K. O.K. E.P. and R.C. were responsible for data collection, data analysis, and data interpretation, and reviewed and approved the manuscript; and M.L. V.N. and J.S.A. were responsible for data analysis, data interpretation, and reviewed and approved the manuscript. Funding Information: This work was made possible through the MGH Lymphoma Translational Research and Biobanking Collaborative supported by the Scott Nathan and Laura DeBonis Fund for Clinical Research (J.S.A.), and further supported by philanthropic funding from an anonymous donor (A.L.), the Jonathan Kraft Translational Research Award (J.D.S. and A.L.), and the National Institutes of Health National Cancer Institute ( 5R01CA196703 ) (R.C.).
PY - 2022/10/20
Y1 - 2022/10/20
UR - http://www.scopus.com/inward/record.url?scp=85139871435&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139871435&partnerID=8YFLogxK
U2 - 10.1182/blood.2022015443
DO - 10.1182/blood.2022015443
M3 - Letter
C2 - 35802834
AN - SCOPUS:85139871435
SN - 0006-4971
VL - 140
SP - 1822
EP - 1826
JO - Blood
JF - Blood
IS - 16
ER -